The finding that miR-125a is up-regulated in tissues of BRAFi-treated melanoma patients as compared to tumor samples excised before BRAF-treatment, allowed Authors to propose the use of anti-miR-125-a for preventing or overcame BRAFi resistance [67]. This evidence concerns the gene BRAF and neoplasm.